Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-7977 plus ribavirin for recurrent chronic hepatitis C after liver transplant
2012-002417-19Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir and ribavirin in hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoint: SVR12. Started Sep 2012; status: completed.
02
Drugs
sofosbuvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2012-002417-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002417-19.